Shedding light on bone morphogenetic protein (BMP) signaling modifiers to modulate fibrodysplasia ossificans progressiva severity

Affiliations

¹Department of Molecular Medicine, Biochemistry Unit, University of Pavia, Pavia, Italy

Links

History

Received: 2022-09-23

Revised: 2022-10-13

Accepted: 2022-10-23

Cited Works (4)

Year	Entry
2016	Wu M, Chen G, Li Y-P. TGF-β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease. Bone Res. 2016;4:16009.
2006	Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho T-J, Choi IH, Connor JM, Delai P, Glaser DL, LeMerrer M, Morhart R, Rogers JG, Smith R, Triffitt JT, Urtizberea JA, Zasloff M, Brown MA, Kaplan FS. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. May 2006;38(5):525-528.
2022	Wentworth KL, Lalonde RL, Groppe JC, Brewer N, Moody T, Hansberry S, Taylor KE, Shore EM, Kaplan FS, Pignolo RJ, Yelick PC, Hsiao EC. Functional testing of bone morphogenetic protein (BMP) pathway variants identified on whole-exome sequencing in a patient with delayed-onset fibrodysplasia ossificans progressiva (FOP) using ACVR1^R206H-specific human cellular and zebrafish models. J Bone Miner Res. November 2022;37(11):2058-2076.
2022	Yamamoto M, Stoessel SJ, Yamamoto S, Goldhamer DJ. Overexpression of wild-type ACVR1 in fibrodysplasia ossificans progressiva mice rescues perinatal lethality and inhibits heterotopic ossification. J Bone Miner Res. November 2022;37(11):2077-2093.